CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has issued an announcement.
CARsgen Therapeutics Holdings Ltd. announced that the research results of their CAR T-cell product, CT071, targeting GPRC5D for newly diagnosed multiple myeloma, have been accepted for a poster presentation at the 2025 European Hematology Association Annual Congress. This development highlights CARsgen’s ongoing efforts to advance their pipeline of CAR T-cell therapies, potentially enhancing their market position in the biopharmaceutical industry by addressing critical treatment challenges in multiple myeloma and related conditions.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biopharmaceutical company specializing in the development of innovative CAR T-cell therapies aimed at addressing unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases. The company has developed comprehensive capabilities in CAR T-cell research, including target discovery, preclinical research, clinical development, and commercial-scale production, with a focus on improving safety, efficacy, and cost-effectiveness of treatments.
YTD Price Performance: 67.21%
Average Trading Volume: 6,479,430
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.82B
For detailed information about 2171 stock, go to TipRanks’ Stock Analysis page.